rttnews.comAUG 32 min read$HELP

Helus Pharma Appoints Michael Halstead CEO, Effective Immediately

According to Cybin D/B/A Helus Pharma (HELP), it appointed Michael Halstead as Chief Executive Officer effective immediately. The company said Halstead has 25 years of industry experience, most recently as President of Intra-Cellular Therapies (ITCI). In Nasdaq pre-market, HELP shares were down 0.90% to $7.75 after Friday’s 3.93% decline.

Original reporting

rttnews.com

Published Aug 3, 2026, 4:15 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 3, 2026, 4:34 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Source · rttnews.com

Decision brief

The 30-second read

$HELPNeutralLow

Why it matters

A new CEO can influence near-term sentiment, but the text lacks any new guidance, trial readouts, or deal activity that would drive a decisive repricing.

Market read

Traders may monitor for follow-on announcements from Helus Pharma, but this specific report contains no new financial or clinical catalysts.

What to watch

Investors will likely wait for Halstead’s first strategic communications, board priorities, and any follow-on changes to R&D or financing plans.

Relevance 4/10Novelty 4/10Timing: effective immediately, pre-market trading context mentioned

Background

The article frames the CEO appointment and Halstead’s prior roles, including President of Intra-Cellular Therapies.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HELPNeutralMedium confidence

Context

Helus Pharma appointed Michael Halstead as CEO effective immediately, a direct leadership change for the company.

Expected impact

Likely limited near-term impact unless accompanied by strategy updates or new clinical/financing milestones.

Evidence & confidence

The only new company-specific fact is the CEO change; there are no new trial results, contracts, or capital actions disclosed.

Market effects

Sector

Leadership changes are common in biotech and can affect perceived execution risk, but no sector-wide signal is provided.

Regional

None indicated beyond Nasdaq pre-market mention.

Global

None indicated.

Counterpoint

What could challenge this read

The market may be overreacting to the CEO headline; without new strategy or pipeline updates, the move may not change fundamentals.

Key entities

company
Helus Pharma
Subject of the article, announcing a CEO appointment effective immediately.
person
Michael Halstead
Incoming CEO with 25 years of industry experience, most recently President of Intra-Cellular Therapies.
company
Intra-Cellular Therapies, Inc.
Most recent employer of the incoming CEO, cited for background only.

Read at source ← All news

JUL 21

$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.

prnewswire.com2 min

JUL 21

$HELPMed

Helus Pharma stock jumps on Phase 3 enrollment completion By Investing.com

Helus Pharma (NASDAQ:HELP) shares rose 12.4% after the company said it completed enrollment in its APPROACH Phase 3 trial of HLP003 for major depressive disorder. The study enrolled 223 adults; topline data are expected in Q4 2026. APPROACH is one of two pivotal trials, with EMBRACE ongoing.

investing.com3 min

JUL 17

$LLYMedAI 8/10

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in milestone-linked contingent value rights, totaling up to about $3.8B. The deal was approved by both boards and is expected to close in Q3. The article cites Helus Pharma (NASDAQ: HELP) Phase 3 readout in Q4 2026.

prnewswire.com7 min

JUN 25

$HELPMedAI 8/10

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said it closed a previously announced underwritten offering of 10,309,280 common shares at US$4.85 each, raising US$50 million in gross proceeds. Cantor and Barclays were joint bookrunners; Bloom Burton and Lucid were lead managers. Net proceeds will fund Phase 3 HLP003 (MDD) with data expected in Q4 2026, plus HLP004 and HLP005, and for working capital.

montrealgazette.com2 min

AUG 8

$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min